Trial Profile
A PHASE 1B STUDY OF THE 4-1BB AGONIST PF-05082566 IN COMBINATION WITH THE PD-1 INHIBITOR MK-3475 IN PATIENTS WITH ADVANCED SOLID TUMORS
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Utomilumab (Primary)
- Indications Colon cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Sarcoma; Small cell lung cancer; Solid tumours; Thymoma; Thyroid cancer
- Focus Adverse reactions
- Acronyms KEYNOTE-0036
- Sponsors Pfizer
- 18 Mar 2022 Results from NCT01307267, NCT02179918 and NCT02444793 comparing the anti drug antibody of utomilumab and its impact on the PK, safety, and efficacy in patients with advanced cancer, presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 14 Mar 2017 Status changed from active, no longer recruiting to completed.
- 23 Feb 2017 Planned number of patients changed from 23 to 45.